S
Salvatore Siena
Researcher at University of Milan
Publications - 572
Citations - 62791
Salvatore Siena is an academic researcher from University of Milan. The author has contributed to research in topics: Colorectal cancer & Panitumumab. The author has an hindex of 91, co-authored 524 publications receiving 53868 citations. Previous affiliations of Salvatore Siena include Novartis & Indiana University.
Papers
More filters
Journal ArticleDOI
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
Jean-Yves Douillard,Kelly S. Oliner,Salvatore Siena,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Richard Thomas Williams,Alan Rong,Jeffrey Wiezorek,Roger Sidhu,Scott D. Patterson +21 more
TL;DR: Additional RAS mutations predicted a lack of response in patients who received panitumumab-FOLFOX4 treatment, which was consistent with the findings in patients with KRAS mutations in exon 2.
Journal ArticleDOI
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
Eric Van Cutsem,Marc Peeters,Salvatore Siena,Yves Humblet,Alain Hendlisz,Bart Neyns,Jean-Luc Canon,Jean-Luc Van Laethem,Joan Maurel,Gary Richardson,Michael S. Wolf,Rafael G. Amado +11 more
TL;DR: Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer and was well tolerated.
Journal ArticleDOI
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale,Rona Yaeger,Sebastijan Hobor,Elisa Scala,Manickam Janakiraman,David Liska,Emanuele Valtorta,Roberta Schiavo,Michela Buscarino,Giulia Siravegna,Katia Bencardino,Andrea Cercek,Chin Tung Chen,Silvio Veronese,Carlo Zanon,Andrea Sartore-Bianchi,Marcello Gambacorta,Margherita Gallicchio,Efsevia Vakiani,Valentina Boscaro,Enzo Medico,Martin R. Weiser,Salvatore Siena,Federica Di Nicolantonio,David B. Solit,Alberto Bardelli +25 more
TL;DR: KRAS mutations are identified as frequent drivers of acquired resistance to cetuximab in colorectal cancers, indicate that the emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression and suggest early initiation of a MEK inhibitor as a rational strategy for delaying or reversing drug resistance.
Journal ArticleDOI
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard,Salvatore Siena,Jim Cassidy,Josep Tabernero,Ronald Burkes,Mario Edmundo Barugel,Yves Humblet,György Bodoky,David Cunningham,Jacek Jassem,Fernando Rivera,Ilona Kocáková,Paul Ruff,Maria Blasinska-Morawiec,Martin Šmakal,Jean-Luc Canon,Mark Rother,Kelly S. Oliner,Michael S. Wolf,Jennifer Gansert +19 more
TL;DR: This study demonstrated that panitumumab-FOLFOX4 was well tolerated and significantly improved PFS in patients with WT KRAS tumors and underscores the importance of KRAS testing for patients with mCRC.
Journal ArticleDOI
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio,Miriam Martini,Francesca Molinari,Andrea Sartore-Bianchi,Sabrina Arena,Piercarlo Saletti,Sara De Dosso,Luca Mazzucchelli,Milo Frattini,Salvatore Siena,Alberto Bardelli +10 more
TL;DR: BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.